Propanc Biopharma Announces New Preclinical And Translational Data For Lead Candidate PRP In Pancreatic Ductal Adenocarcinoma
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,
Propanc shared new research results showing their medicine candidate PRP might help fight a serious type of pancreatic cancer. When a medicine company shows promising early research, it's a sign they're making progress, though many medicines don't make it to patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.